

Graeme Eisenhofer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6511966/publications.pdf>

Version: 2024-02-01

494
papers

32,470
citations

3334

91
h-index

6131

159
g-index

514
all docs

514
docs citations

514
times ranked

17958
citing authors

#	ARTICLE	IF	CITATIONS
1	Scoping review of COVID-19-related systematic reviews and meta-analyses: can we really have confidence in their results?. <i>Postgraduate Medical Journal</i> , 2022, 98, 372-379.	1.8	5
2	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	20.1	127
3	Hypoxia-inducible Factor 2 β : A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, 282-289.	1.2	12
4	Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2022, 75, 254-265.	2.3	3
5	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. <i>World Journal of Urology</i> , 2022, 40, 385-390.	2.2	8
6	Plasma Steroid Profiling in Patients With Adrenal Incidentaloma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1181-e1192.	3.6	19
7	Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model. <i>Cells</i> , 2022, 11, 560.	4.1	2
8	Report from the HarmoSter study: impact of calibration on comparability of LC-MS/MS measurement of circulating cortisol, 17OH-progesterone and aldosterone. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 726-739.	2.3	11
9	Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis. <i>Neuro-Oncology</i> , 2022, 24, 1509-1523.	1.2	12
10	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306.	3.1	12
11	Angpt2/Tie2 autostimulatory loop controls tumorigenesis. <i>EMBO Molecular Medicine</i> , 2022, 14, e14364.	6.9	7
12	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. <i>Endocrine-Related Cancer</i> , 2022, 29, 213-224.	3.1	12
13	The Saline Infusion Test for Primary Aldosteronism: Implications of Immunoassay Inaccuracy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2027-e2036.	3.6	27
14	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. <i>Hypertension</i> , 2022, 79, 1257-1264.	2.7	8
15	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. <i>European Journal of Cancer</i> , 2022, 169, 32-41.	2.8	18
16	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3689-e3698.	3.6	4
17	Integration of artificial intelligence and plasma steroidomics with laboratory information management systems: application to primary aldosteronism. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1929-1937.	2.3	6
18	Volumetric Modeling of Adrenal Gland Size in Primary Bilateral Macronodular Adrenocortical Hyperplasia. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa162.	0.2	7

#	ARTICLE	IF	CITATIONS
19	Pregnancy and pheochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome – a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1264-1272.	2.3	14
20	The longevity gene mIndy (lâ€™m Not Dead, Yet) affects blood pressure through sympathoadrenal mechanisms. <i>JCI Insight</i> , 2021, 6, .	5.0	17
21	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	10.0	70
22	Loss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics. <i>Endocrine-Related Cancer</i> , 2021, 28, 65-77.	3.1	9
23	Intrarenal hemodynamics and kidney function in pheochromocytoma and paraganglioma before and after surgical treatment. <i>Blood Pressure</i> , 2021, 30, 1-8.	1.5	0
24	Functional significance of germline EPAS1 variants. <i>Endocrine-Related Cancer</i> , 2021, 28, 97-109.	3.1	6
25	Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion. <i>Discover Oncology</i> , 2021, 12, 9.	2.1	5
26	Adrenal Hormone Interactions and Metabolism: A Single Sample Multi-Omics Approach. <i>Hormone and Metabolic Research</i> , 2021, 53, 326-334.	1.5	8
27	Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension. <i>Clinical Autonomic Research</i> , 2021, 31, 351-353.	2.5	1
28	Harmonization of LC-MS/MS Measurements of Plasma Free Normetanephrine, Metanephrine, and 3-Methoxytyramine. <i>Clinical Chemistry</i> , 2021, 67, 1098-1112.	3.2	20
29	The role of regulated necrosis in endocrine diseases. <i>Nature Reviews Endocrinology</i> , 2021, 17, 497-510.	9.6	35
30	Optimized procedures for testing plasma metanephrines in patients on hemodialysis. <i>Scientific Reports</i> , 2021, 11, 14706.	3.3	5
31	HIF2 β regulates the synthesis and release of epinephrine in the adrenal medulla. <i>Journal of Molecular Medicine</i> , 2021, 99, 1655-1666.	3.9	9
32	Analysis of Telomere Maintenance Related Genes Reveals NOP10 as a New Metastatic-Risk Marker in Pheochromocytoma/Paraganglioma. <i>Cancers</i> , 2021, 13, 4758.	3.7	14
33	HIF1 β is a direct regulator of steroidogenesis in the adrenal gland. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3577-3590.	5.4	15
34	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 353-363.	2.3	32
35	Impact of Dietary Sodium Reduction on the Development of Obesity and Type 2 Diabetes in db/db Mice. <i>Hormone and Metabolic Research</i> , 2021, 53, 699-704.	1.5	1
36	Targeted Quantification of Carbon Metabolites Identifies Metabolic Progression Markers and an Undiagnosed Case of SDH-Deficient Clear Cell Renal Cell Carcinoma in a German Cohort. <i>Metabolites</i> , 2021, 11, 764.	2.9	1

#	ARTICLE	IF	CITATIONS
37	Biochemical testing for neuroblastoma using plasma free 3-methyl-dopa, 3-methoxytyramine, and normetanephrine. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28081.	1.5	14
38	Effect of Dietary Sodium Modulation on Pig Adrenal Steroidogenesis and Transcriptome Profiles. <i>Hypertension</i> , 2020, 76, 1769-1777.	2.7	5
39	Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism. <i>JAMA Network Open</i> , 2020, 3, e2016209.	5.9	53
40	Differential Responses of Urinary Epinephrine and Norepinephrine to 24-h Shift-Work Stressor in Physicians. <i>Frontiers in Endocrinology</i> , 2020, 11, 572461.	3.5	4
41	Adrenocortical carcinomas and malignant pheochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1476-1490.	1.2	209
42	Left Ventricular Structural and Functional Alterations in Patients With Pheochromocytoma/Paraganglioma Before and After Surgery. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2498-2509.	5.3	18
43	SUN-222 Pre- and Post-Pubertal Reference Ranges for Oxygenated Androgens in Saliva. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
44	Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa102.	0.2	56
45	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 773-781.	11.4	129
46	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3295-3307.	3.6	34
47	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. <i>Journal of Hypertension</i> , 2020, 38, 1551-1558.	0.5	3
48	Pheochromocytoma " advances through science, collaboration and spreading the word. <i>Nature Reviews Endocrinology</i> , 2020, 16, 621-622.	9.6	8
49	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. <i>Molecular Psychiatry</i> , 2020, 25, 1611-1617.	7.9	70
50	Commentary on Cryptogenic Cushing Syndrome Due to a White Lie. <i>Clinical Chemistry</i> , 2020, 66, 661-662.	3.2	1
51	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in pheochromocytomas and paragangliomas. <i>Journal of Pathology</i> , 2020, 251, 378-387.	4.5	23
52	Endocrine Conditions and COVID-19. <i>Hormone and Metabolic Research</i> , 2020, 52, 471-484.	1.5	34
53	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154297.	3.4	11
54	Cancer Stem Cells in Pheochromocytoma and Paraganglioma. <i>Frontiers in Endocrinology</i> , 2020, 11, 79.	3.5	20

#	ARTICLE	IF	CITATIONS
55	Glucocorticoid Excess in Patients with Pheochromocytoma Compared with Paraganglioma and Other Forms of Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3374-e3383.	3.6	17
56	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456.	0.5	190
57	Mass spectrometry reveals misdiagnosis of primary aldosteronism with scheduling for adrenalectomy due to immunoassay interference. <i>Clinica Chimica Acta</i> , 2020, 507, 98-103.	1.1	8
58	Generation and characterization of a mitotane-resistant adrenocortical cell line. <i>Endocrine Connections</i> , 2020, 9, 122-134.	1.9	11
59	Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?. <i>European Journal of Endocrinology</i> , 2020, 182, 499-509.	3.7	13
60	Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. <i>Endocrine-Related Cancer</i> , 2020, 27, 403-413.	3.1	13
61	HIF2 α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640.	3.1	33
62	Blood sampling for metanephrines: to stick or stick and wait?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1609-1610.	2.3	0
63	MON-199 Targeting Pheochromocytoma/Paraganglioma with Polyamine Inhibitors. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
64	Blood pressure profile, sympathetic nervous system activity and subclinical target organ damage in patients with polycythemia vera. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 607-614.	0.4	3
65	Pheochromocytoma Concealed By Chronic Methamphetamine Abuse. <i>AACE Clinical Case Reports</i> , 2020, 6, e212-e216.	1.1	3
66	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , 2019, 21, 705-717.	2.4	60
67	Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2019, 11, 1121.	3.7	36
68	Steroid metabolomics: machine learning and multidimensional diagnostics for adrenal cortical tumors, hyperplasias, and related disorders. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 40-49.	1.4	8
69	Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma. <i>Theranostics</i> , 2019, 9, 4946-4958.	10.0	54
70	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	3.7	120
71	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617.	2.8	24
72	Plasma Steroid Profiles in Subclinical Compared With Overt Adrenal Cushing Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4331-4340.	3.6	35

#	ARTICLE	IF	CITATIONS
73	Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism—a Review. <i>Current Hypertension Reports</i> , 2019, 21, 77.	3.5	17
74	Steroid Profiling as an Additional Tool to Confirm One-Sided Hormone Overproduction in Primary Aldosteronism: A Case Report. <i>Frontiers in Endocrinology</i> , 2019, 10, 597.	3.5	2
75	New Way Forward for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Tumors with an LC-MS/MS Panel of Indole Biomarkers. <i>Clinical Chemistry</i> , 2019, 65, 1346-1347.	3.2	1
76	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	7.0	53
77	The Catalytic Subunit \hat{I}^2 of PKA Affects Energy Balance and Catecholaminergic Activity. <i>Journal of the Endocrine Society</i> , 2019, 3, 1062-1078.	0.2	9
78	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , 2019, 11, 809.	3.7	23
79	Development of a Function-Integrative Sleeve for Medical Applications. <i>Sensors</i> , 2019, 19, 2588.	3.8	3
80	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. <i>Cancers</i> , 2019, 11, 743.	3.7	6
81	Pheochromocytoma and Pregnancy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 605-617.	3.2	42
82	A Transgenic Mouse Model of Pacak’s “Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. <i>Cancers</i> , 2019, 11, 667.	3.7	22
83	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2 \hat{I} ± in Pheochromocytoma Cells. <i>Cancers</i> , 2019, 11, 594.	3.7	24
84	Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy. <i>Clinica Chimica Acta</i> , 2019, 494, 100-105.	1.1	29
85	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3812-3820.	3.6	19
86	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas. <i>American Journal of Human Genetics</i> , 2019, 104, 651-664.	6.2	51
87	Novel methods in adrenal research: a metabolomics approach. <i>Histochemistry and Cell Biology</i> , 2019, 151, 201-216.	1.7	10
88	The Adrenal Gland: Central Relay in Health and Disease. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 81-83.	1.2	5
89	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. <i>Cancers</i> , 2019, 11, 2028.	3.7	23
90	Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. <i>Journal of Cellular Biotechnology</i> , 2019, 5, 135-151.	0.5	8

#	ARTICLE	IF	CITATIONS
91	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. <i>Clinica Chimica Acta</i> , 2019, 490, 46-54.	1.1	50
92	A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 188, 38-47.	2.5	4
93	Classification of microadenomas in patients with primary aldosteronism by steroid profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 274-282.	2.5	28
94	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. <i>Molecular Psychiatry</i> , 2019, 24, 2-9.	7.9	21
95	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. <i>International Journal of Obesity</i> , 2019, 43, 263-275.	3.4	12
96	Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases. <i>JCI Insight</i> , 2019, 4, .	5.0	22
97	Pheochromocytoma and Paraganglioma. , 2019, , 523-531.		3
98	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. <i>European Journal of Endocrinology</i> , 2019, 181, 409-420.	3.7	58
99	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. <i>European Journal of Endocrinology</i> , 2019, 181, 647-657.	3.7	19
100	OR02-6 Mass Spectrometry-Based Steroid Profiling Inprimary Bilateral Macronodular Adrenocortical Hyperplasia. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
101	Catecholamines. , 2018, , 21-24.		3
102	Compensation for chronic oxidative stress in ALADIN null mice. <i>Biology Open</i> , 2018, 7, .	1.2	2
103	Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome. <i>Gynecological Endocrinology</i> , 2018, 34, 20-24.	1.7	17
104	Plasma Steroid Metabolome Profiling for Diagnosis and Subtyping Patients with Cushing Syndrome. <i>Clinical Chemistry</i> , 2018, 64, 586-596.	3.2	70
105	Next-generation panel sequencing identifies NF1 germline mutations in three patients with pheochromocytoma but no clinical diagnosis of neurofibromatosis type 1. <i>European Journal of Endocrinology</i> , 2018, 178, K1-K9.	3.7	19
106	Biochemical Diagnosis of Pheochromocytoma, a Rediscovered Catecholamine-Metabolizing Tumor. <i>Clinical Chemistry</i> , 2018, 64, 1780-1781.	3.2	11
107	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. <i>Cell and Tissue Research</i> , 2018, 374, 473-485.	2.9	23
108	OC-0152: Glutamine metabolism as potential biomarker and target for prostate cancer radiosensitization. <i>Radiotherapy and Oncology</i> , 2018, 127, S76-S77.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Anti-Tumorigenic and Anti-Metastatic Activity of the Sponge-Derived Marine Drugs Aerophysinin-1 and Isofistularin-3 against Pheochromocytoma In Vitro. <i>Marine Drugs</i> , 2018, 16, 172.	4.6	39
110	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , 2018, 20, 1652-1662.	2.4	45
111	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	2.7	51
112	A pedunculated aldosterone-producing adenoma drained by an extra vein causing puzzling results of adrenal vein sampling. <i>Clinical Endocrinology</i> , 2018, 89, 242-244.	2.4	3
113	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. <i>Clinical Chemistry</i> , 2018, 64, 1646-1656.	3.2	121
114	Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 907-909.	1.9	19
115	Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging. <i>Endocrine Connections</i> , 2018, 7, 1168-1177.	1.9	11
116	Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. <i>Endocrine-Related Cancer</i> , 2018, 25, 993-1004.	3.1	6
117	Paroxysmal Hypertension: Pheochromocytoma. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2018, , 541-560.	0.1	0
118	Normetanephrine and Metanephrine. , 2017, , 420-424.		1
119	Tumor Metabolism and Metabolomics of Pheochromocytomas and Paragangliomas. , 2017, , 239-250.		0
120	Adrenal medullary dysfunction as a feature of obesity. <i>International Journal of Obesity</i> , 2017, 41, 714-721.	3.4	21
121	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. <i>Endocrine</i> , 2017, 56, 495-503.	2.3	79
122	Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. <i>European Journal of Endocrinology</i> , 2017, 177, 103-113.	3.7	82
123	Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. <i>Clinica Chimica Acta</i> , 2017, 470, 115-124.	1.1	116
124	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1122-1132.	3.6	120
125	Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with Primary Aldosteronism. <i>Hormone and Metabolic Research</i> , 2017, 49, 418-423.	1.5	5
126	The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice. <i>Hormone and Metabolic Research</i> , 2017, 49, 466-471.	1.5	4

#	ARTICLE	IF	CITATIONS
127	Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy. American Journal of Human Genetics, 2017, 100, 151-159.	6.2	63
128	Steroid Profiling for Adrenocortical Disorders: A Pathway for Omics-Based Diagnostics. Clinical Chemistry, 2017, 63, 1787-1789.	3.2	8
129	The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564.	3.1	26
130	Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Associated Predisposing Mutations in Pheochromocytomas and Paragangliomas. Clinical Cancer Research, 2017, 23, 6315-6324.	7.0	73
131	Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical Cells. Hormone and Metabolic Research, 2017, 49, 701-706.	1.5	3
132	Subtyping of Patients with Primary Aldosteronism: An Update. Hormone and Metabolic Research, 2017, 49, 922-928.	1.5	32
133	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
134	Elevated Steroid Hormone Production in the db/db Mouse Model of Obesity and Type 2 Diabetes. Hormone and Metabolic Research, 2017, 49, 43-49.	1.5	28
135	Adrenal cortical and chromaffin stem cells: Is there a common progeny related to stress adaptation?. Molecular and Cellular Endocrinology, 2017, 441, 156-163.	3.2	21
136	Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinology and Metabolism, 2017, 32, 152.	3.0	113
137	Abstract 3391: Next generation sequencing paves the way for personalized medicine in pheochromocytoma and paraganglioma patients and their families. , 2017, , .		0
138	Metabologenomics of Pheochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clinical Biochemist Reviews, 2017, 38, 69-100.	3.3	46
139	Multimodal Somatostatin Receptor Theranostics Using [⁶⁴ Cu]Cu-/[¹⁷⁷ Lu]Lu-DOTA-(Tyr ³)octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics, 2016, 6, 650-665.	10.0	38
140	Resection of Pheochromocytoma in a Patient Requiring Coronary Artery Bypass Grafting: First Things First. AACE Clinical Case Reports, 2016, 2, e25-e29.	1.1	2
141	Beyond a Disease Registry: An Integrated Virtual Environment for Adrenal Cancer Research. Journal of Grid Computing, 2016, 14, 515-532.	3.9	8
142	Hypoxia-Inducible Factor 2 [±] Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. Neoplasia, 2016, 18, 567-576.	5.3	16
143	Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats. Endocrinology, 2016, 157, 3844-3855.	2.8	14
144	PRKACA Somatic Mutations Are Rare Findings in Aldosterone-Producing Adenomas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3010-3017.	3.6	43

#	ARTICLE	IF	CITATIONS
145	Morphology, Biochemistry, and Pathophysiology of MENX-Related Pheochromocytoma Recapitulate the Clinical Features. <i>Endocrinology</i> , 2016, 157, 3157-3166.	2.8	10
146	Arterio-venous differences in cord levels of catecholamines, glucose, lactate and blood gases. <i>Journal of Perinatal Medicine</i> , 2016, 44, 695-704.	1.4	3
147	Mass Spectrometry-Based Adrenal and Peripheral Venous Steroid Profiling for Subtyping Primary Aldosteronism. <i>Clinical Chemistry</i> , 2016, 62, 514-524.	3.2	123
148	Genotype-Specific Steroid Profiles Associated With Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2016, 67, 139-145.	2.7	127
149	Dipping in Ambulatory Blood Pressure Monitoring Correlates With Overnight Urinary Excretion of Catecholamines and Sodium. <i>Journal of Clinical Hypertension</i> , 2016, 18, 921-926.	2.0	12
150	Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 359-363.	3.6	42
151	Impact of LC-MS/MS on the laboratory diagnosis of catecholamine-producing tumors. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 106-116.	11.4	28
152	Adipocyte-Specific Hypoxia-Inducible Factor 2 α Deficiency Exacerbates Obesity-Induced Brown Adipose Tissue Dysfunction and Metabolic Dysregulation. <i>Molecular and Cellular Biology</i> , 2016, 36, 376-393.	2.3	63
153	Computational analysis of liquid chromatography-tandem mass spectrometric steroid profiling in NCI H295R cells following angiotensin II, forskolin and abiraterone treatment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 67-75.	2.5	12
154	Preservation of urine free catecholamines and their free O-methylated metabolites with citric acid as an alternative to hydrochloric acid for LC-MS/MS-based analyses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 37-43.	2.3	10
155	Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150117.	0.5	2
156	Abstract LB-308: Effects of the IDH1 R132H mutation on redox status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation. , 2016, , .		0
157	Maternal and fetal factors which influence cord blood glucose levels in term infants delivered by cesarean section. <i>Journal of Perinatal Medicine</i> , 2015, 43, 339-346.	1.4	4
158	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821.	5.5	176
159	Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. <i>Molecular Psychiatry</i> , 2015, 20, 941-950.	7.9	26
160	Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 89-95.	3.7	17
161	Steroid Hormone Production in Patients with Aldosterone Producing Adenomas. <i>Hormone and Metabolic Research</i> , 2015, 47, 967-972.	1.5	14
162	Genotype-Specific Differences in the Tumor Metabolite Profile of Pheochromocytoma and Paraganglioma Using Untargeted and Targeted Metabolomics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E214-E222.	3.6	33

#	ARTICLE	IF	CITATIONS
163	Diagnosing pheochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. <i>Clinical Endocrinology</i> , 2015, 83, 298-302.	2.4	35
164	Whole-Exome Sequencing Identifies MDH2 as a New Familial Paraganglioma Gene. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	143
165	Interference from 3-O-Methyldopa with Ultra-High Performance LC-MS/MS Measurements of Plasma Metanephrines: Chromatographic Separation Remains Important. <i>Clinical Chemistry</i> , 2015, 61, 993-996.	3.2	27
166	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 251-260.	3.7	47
167	DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 3020-3030.	7.0	53
168	Supine or Sitting? Economic and other considerations for use of plasma metanephrines for diagnosis of pheochromocytoma. <i>Clinical Endocrinology</i> , 2015, 82, 463-464.	2.4	11
169	An LC-MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 75-84.	2.5	129
170	Changes in morphology and function of adrenal cortex in mice fed a high-fat diet. <i>International Journal of Obesity</i> , 2015, 39, 321-330.	3.4	41
171	Abstract 543: Impact of Eplerenone on Vascular Function in LOX-1 Overexpressing Mice on High-Fat Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	2.4	0
172	Pheochromocytoma Presenting as Takotsubo-Like Cardiomyopathy Following Delivery. <i>Endocrine Practice</i> , 2014, 20, 233-236.	2.1	8
173	Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3903-3911.	3.6	111
174	Pathophysiology and Diagnosis of Disorders of the Adrenal Medulla: Focus on Pheochromocytoma. , 2014, 4, 691-713.		24
175	A Defined, Controlled Culture System for Primary Bovine Chromaffin Progenitors Reveals Novel Biomarkers and Modulators. <i>Stem Cells Translational Medicine</i> , 2014, 3, 801-808.	3.3	8
176	Genetics and the Clinical Approach to Paragangliomas. <i>Hormone and Metabolic Research</i> , 2014, 46, 964-973.	1.5	7
177	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 182-188.	2.5	52
178	Closing the GAPP on predicting metastases. <i>Nature Reviews Endocrinology</i> , 2014, 10, 315-316.	9.6	24
179	Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paraganglioma: Initial Experimental and Ex Vivo Findings. <i>Endocrinology</i> , 2014, 155, 27-32.	2.8	63
180	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. <i>Endocrinology</i> , 2014, 155, 4149-4156.	2.8	16

#	ARTICLE	IF	CITATIONS
181	Pitfalls in Genetic Analysis of Pheochromocytomas/Paragangliomasâ€”Case Report. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2321-2326.	3.6	8
182	Laboratory Evaluation of Pheochromocytoma and Paraganglioma. <i>Clinical Chemistry</i> , 2014, 60, 1486-1499.	3.2	161
183	Biochemical diagnosis of pheochromocytoma using plasmaâ€”free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. <i>Clinical Endocrinology</i> , 2014, 80, 478-486.	2.4	96
184	Clinical utility of chromogranin A in <i>SDH</i> -related paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014, 44, 365-371.	3.4	40
185	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. <i>European Journal of Endocrinology</i> , 2014, 170, 349-357.	3.7	25
186	Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 9-16.	1.4	15
187	Seasonal variations of plasma normetanephrine levels: the authors reply. <i>European Journal of Endocrinology</i> , 2014, 170, L3.	3.7	2
188	The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now. <i>Endocrine Pathology</i> , 2014, 25, 49-58.	9.0	39
189	Levodopa therapy in Parkinsonâ€™s disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 38-46.	1.6	26
190	Opposing effects of HIF1 α and HIF2 α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. <i>International Journal of Cancer</i> , 2014, 135, 2054-2064.	5.1	72
191	Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1915-1942.	3.6	2,031
192	Time matters â€” Acute stress response and glucocorticoid sensitivity in early multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 82-89.	4.1	16
193	Impact of mineralocorticoid receptor blockade on vascular function in atherosclerotic mouse models under high-fat diet. <i>Atherosclerosis</i> , 2014, 235, e152-e153.	0.8	0
194	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1713-1719.	3.7	4
195	Plasmaâ€”free <i>vs</i> deconjugated metanephrines for diagnosis of pheochromocytoma. <i>Clinical Endocrinology</i> , 2013, 79, 476-483.	2.4	15
196	Role of Hypoxia and HIF2 α in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. <i>Advances in Pharmacology</i> , 2013, 68, 285-317.	2.0	34
197	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 62-69.	1.6	98
198	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 147-155.	1.6	99

#	ARTICLE	IF	CITATIONS
199	Simultaneous liquid chromatography tandem mass spectrometric determination of urinary free metanephrines and catecholamines, with comparisons of free and deconjugated metabolites. <i>Clinica Chimica Acta</i> , 2013, 418, 50-58.	1.1	82
200	Pheochromocytoma and Gastrointestinal Stromal Tumors in Patients With Neurofibromatosis Type I. <i>American Journal of Medicine</i> , 2013, 126, 174-180.	1.5	35
201	Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells. <i>Molecular and Cellular Endocrinology</i> , 2013, 371, 189-194.	3.2	8
202	Pheochromocytoma. <i>Clinical Chemistry</i> , 2013, 59, 466-472.	3.2	29
203	Metabolomic distinction of microvascular effects of lipoprotein apheresis—A pilot study. <i>Atherosclerosis Supplements</i> , 2013, 14, 143-149.	1.2	5
204	Mortality Associated with Pheochromocytoma. <i>Hormone and Metabolic Research</i> , 2013, 45, 154-158.	1.5	45
205	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. <i>Neuro-Oncology</i> , 2013, 15, 682-690.	1.2	26
206	Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2013, 19, 3787-3795.	7.0	53
207	Plasma Metanephrine for Assessing the Selectivity of Adrenal Venous Sampling. <i>Hypertension</i> , 2013, 62, 1152-1157.	2.7	65
208	Labordiagnostik Katecholamin-produzierender Tumoren. <i>Laboratoriums Medizin</i> , 2013, 37, 187-197.	0.6	0
209	Commentary. <i>Clinical Chemistry</i> , 2013, 59, 1565-1566.	3.2	3
210	Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography. <i>Journal of the National Cancer Institute</i> , 2012, 104, 700-708.	6.3	240
211	Pheochromocytoma and Paraganglioma: Recent Progress and New Vistas for Improved Patient Care. <i>Hormone and Metabolic Research</i> , 2012, 44, 325-327.	1.5	8
212	Combined Use of 68Ga-DOTATATE and 18F-FDG PET/CT to Localize a Bronchial Carcinoid Associated with Ectopic ACTH Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2207-2208.	3.6	13
213	Genetic Screening for von Hippel-Lindau Gene Mutations in Non-syndromic Pheochromocytoma: Low Prevalence and False-positives or Misdiagnosis Indicate a Need for Caution. <i>Hormone and Metabolic Research</i> , 2012, 44, 343-348.	1.5	11
214	Pheochromocytoma—update on disease management. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2012, 3, 11-26.	3.2	70
215	MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2012, 18, 2828-2837.	7.0	277
216	Differentiation of Chromaffin Progenitor Cells to Dopaminergic Neurons. <i>Cell Transplantation</i> , 2012, 21, 2471-2486.	2.5	23

#	ARTICLE	IF	CITATIONS
217	Rapid circulatory clearances and half-lives of plasma free metanephrines. <i>Clinical Endocrinology</i> , 2012, 77, 484-485.	2.4	12
218	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. <i>Nuclear Medicine and Biology</i> , 2012, 39, 215-226.	0.6	13
219	Subclinical pheochromocytoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2012, 26, 507-515.	4.7	76
220	Regulation of thrombomodulin expression in prostate cancer cells. <i>Cancer Letters</i> , 2012, 322, 177-184.	7.2	11
221	Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. <i>European Journal of Cancer</i> , 2012, 48, 1739-1749.	2.8	304
222	Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells. <i>BMC Cancer</i> , 2012, 12, 576.	2.6	30
223	Chromaffin cells: the peripheral brain. <i>Molecular Psychiatry</i> , 2012, 17, 354-358.	7.9	33
224	Dopaminergic Neurotransmission. , 2012, , 63-65.		1
225	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. <i>Cancer Investigation</i> , 2012, 30, 343-363.	1.3	9
226	Autonomic Nervous System Function in Rheumatoid Arthritis. <i>Cellular and Molecular Neurobiology</i> , 2012, 32, 897-901.	3.3	20
227	Screening for Pheochromocytomas and Paragangliomas. <i>Current Hypertension Reports</i> , 2012, 14, 130-137.	3.5	34
228	Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification. <i>Endocrine Pathology</i> , 2012, 23, 4-14.	9.0	95
229	Catecholamines and Serotonin. , 2012, , 851-894.		4
230	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. <i>Clinical Chemistry</i> , 2011, 57, 411-420.	3.2	282
231	Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. <i>Molecular and Cellular Endocrinology</i> , 2011, 335, 69-77.	3.2	7
232	Direct effect of dehydroepiandrosterone sulfate (DHEAS) on PC-12 cell differentiation processes. <i>Molecular and Cellular Endocrinology</i> , 2011, 336, 149-155.	3.2	14
233	Cardiovascular manifestations of pheochromocytoma. <i>Journal of Hypertension</i> , 2011, 29, 2049-2060.	0.5	224
234	Is there still a place for adrenal venous sampling in the diagnostic localization of pheochromocytoma?. <i>Endocrine</i> , 2011, 40, 75-79.	2.3	6

#	ARTICLE	IF	CITATIONS
235	Expression and shedding of endothelial protein C receptor in prostate cancer cells. <i>Cancer Cell International</i> , 2011, 11, 4.	4.1	11
236	Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 375-384.	3.6	90
237	A patient with a large recurrent pheochromocytoma demonstrating the pitfalls of diagnosis. <i>Nature Reviews Endocrinology</i> , 2011, 7, 749-755.	9.6	12
238	Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to <i>SDHB</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 4137-4142.	1.6	170
239	Pheochromocytoma or Munchausen syndrome: the masquerade is up. <i>Clinical Autonomic Research</i> , 2010, 20, 211-212.	2.5	3
240	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2010, 18, 97-111.	3.1	169
241	Risks of hemodynamic instability in pheochromocytoma. <i>Nature Reviews Endocrinology</i> , 2010, 6, 301-302.	9.6	12
242	Adrenomedullary Function in Patients with Nonclassic Congenital Adrenal Hyperplasia. <i>Hormone and Metabolic Research</i> , 2010, 42, 607-612.	1.5	19
243	Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 238-245.	3.6	27
244	31 ACTIVE SURVEILLANCE OF PHEO IN VON HIPPEL-LINDAU (VHL) PATIENTS: EVALUATION OF SAFETY AND GROWTH RATES. <i>Journal of Urology</i> , 2010, 183, .	0.4	1
245	Reducing agents induce thrombomodulin shedding in human endothelial cells. <i>Thrombosis Research</i> , 2010, 126, e88-e93.	1.7	19
246	Phäochromozytom – Paragangliom. , 2010, , 270-277.		0
247	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. <i>Hormones</i> , 2009, 8, 111-116.	1.9	36
248	Simultaneous Liquid-Chromatographic Determination of Plasma Catecholamines and Metabolites. <i>Clinical Chemistry</i> , 2009, 55, 2223-2224.	3.2	4
249	Genetic markers for the diagnosis and prognosis of pheochromocytoma. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 45-52.	2.4	3
250	Dietary Influences on Plasma and Urinary Metanephrines: Implications for Diagnosis of Catecholamine-Producing Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2841-2849.	3.6	131
251	Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4757-4767.	3.6	361
252	Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: Antiproliferative effects of peptide analogues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15879-15884.	7.1	44

#	ARTICLE	IF	CITATIONS
253	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. <i>Endocrine-Related Cancer</i> , 2009, 16, 291-299.	3.1	42
254	Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. <i>Experimental Cell Research</i> , 2009, 315, 2673-2682.	2.6	64
255	Update on pediatric pheochromocytoma. <i>Pediatric Nephrology</i> , 2009, 24, 943-950.	1.7	102
256	Use of ^{18}F -fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma (PHEO). <i>Clinical Endocrinology</i> , 2009, 71, 11-17.	2.4	74
257	Dehydroepiandrosterone-sulphate (DHEA-S) promotes neuroendocrine differentiation of chromaffin pheochromocytoma PC12 cells. <i>Molecular and Cellular Endocrinology</i> , 2009, 300, 126-131.	3.2	10
258	Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. <i>Annals of Surgery</i> , 2009, 250, 983-990.	4.2	23
259	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. <i>Endocrine</i> , 2008, 34, 96-100.	2.3	16
260	Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 469-478.	3.8	15
261	Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 462-468.	3.8	22
262	Mutations associated with succinate dehydrogenase-related malignant paragangliomas. <i>Clinical Endocrinology</i> , 2008, 68, 561-566.	2.4	44
263	Involvement of Epigenetic Mechanisms in the Regulation of Secreted Phospholipase A2 Expressions in Jurkat Leukemia Cells. <i>Neoplasia</i> , 2008, 10, 1195-1203.	5.3	16
264	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E1223-E1233.	3.5	66
265	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. <i>Endocrine-Related Cancer</i> , 2008, 15, 311-323.	3.1	60
266	Current Progress and Future Challenges in the Biochemical Diagnosis and Treatment of Pheochromocytomas and Paragangliomas. <i>Hormone and Metabolic Research</i> , 2008, 40, 329-337.	1.5	94
267	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. <i>European Journal of Endocrinology</i> , 2008, 158, 423-429.	3.7	86
268	Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the Succinate Dehydrogenase Subunit B Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4826-4832.	3.6	111
269	Cure of Neuroendocrine Carcinoma by Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2008, 33, 690-691.	1.3	6
270	High-Throughput, Automated, and Accurate Biochemical Screening for Pheochromocytoma: Are We There Yet?. <i>Clinical Chemistry</i> , 2007, 53, 1565-1567.	3.2	14

#	ARTICLE	IF	CITATIONS
271	The Incidentally Discovered Adrenal Mass. <i>New England Journal of Medicine</i> , 2007, 356, 2005-2006.	27.0	20
272	Chromogranin A Expression in Pheochromocytomas Associated with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. <i>Hormone and Metabolic Research</i> , 2007, 39, 876-883.	1.5	16
273	Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glycemic Control during Prolonged Moderate-Intensity Exercise. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3019-3024.	3.6	40
274	Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 779-786.	3.6	262
275	The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1599-1606.	5.0	101
276	Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1940-1944.	5.0	23
277	Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. <i>Clinical Chemistry</i> , 2007, 53, 352-354.	3.2	110
278	Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2262-2269.	1.6	316
279	Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. <i>Endocrine-Related Cancer</i> , 2007, 14, 463-471.	3.1	14
280	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 483-487.	3.7	78
281	Neuropeptide Y expression in pheochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. <i>Journal of Endocrinology</i> , 2007, 193, 225-233.	2.6	14
282	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. <i>Journal of Hypertension</i> , 2007, 25, 2286-2295.	0.5	42
283	Current Treatment of Malignant Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1217-1225.	3.6	180
284	Adverse Drug Reactions in Patients with Pheochromocytoma. <i>Drug Safety</i> , 2007, 30, 1031-1062.	3.2	122
285	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 92-102.	2.8	581
286	An assessment of biochemical tests for the diagnosis of pheochromocytoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 744-745.	2.8	19
287	Dopamine lesion-induced changes in subthalamic nucleus activity are not associated with alterations in firing rate or pattern in layer V neurons of the anterior cingulate cortex in anesthetized rats. <i>European Journal of Neuroscience</i> , 2007, 26, 1925-1939.	2.6	32
288	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. <i>Clinical Autonomic Research</i> , 2007, 17, 118-121.	2.5	88

#	ARTICLE	IF	CITATIONS
289	Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 699-724.	3.2	65
290	Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. <i>Endocrine Practice</i> , 2006, 12, 568-571.	2.1	9
291	1,111 Patients with Adrenal Incidentalomas Observed at a Single Endocrinological Center: Incidence of Chromaffin Tumors. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 38-46.	3.8	65
292	Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 241-252.	3.8	24
293	Gene Expression Profiling of Rat Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 290-299.	3.8	6
294	Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 332-347.	3.8	115
295	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 541-556.	3.8	59
296	Clinical Catecholamine Neurochemistry: A Legacy of Julius Axelrod. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 693-700.	3.3	13
297	Pheochromocytoma: recent advances and speed bumps in the road to further progress. <i>Journal of Hypertension</i> , 2006, 24, 2341-2343.	0.5	5
298	High Frequency of <i>SDHB</i> Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4505-4509.	3.6	299
299	Sympathoadrenal function in patients with paroxysmal hypertension. <i>FASEB Journal</i> , 2006, 20, A1184.	0.5	0
300	High-Throughput Molecular and Histopathologic Profiling of the Tumor Microenvironment in A Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. <i>Journal of Immunotherapy</i> , 2005, 28, 638-639.	2.4	0
301	Plasma metanephrines in renal failure. <i>Kidney International</i> , 2005, 67, 668-677.	5.2	73
302	Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. <i>Journal of Internal Medicine</i> , 2005, 257, 60-68.	6.0	85
303	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. <i>International Journal of Cancer</i> , 2005, 114, 139-143.	5.1	92
304	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. <i>Cell and Tissue Research</i> , 2005, 322, 443-453.	2.9	22
305	Sympathetic nerve function. <i>Clinical Autonomic Research</i> , 2005, 15, 264-283.	2.5	22
306	Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. <i>Clinical Chemistry</i> , 2005, 51, 735-744.	3.2	177

#	ARTICLE	IF	CITATIONS
307	Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2068-2075.	3.6	213
308	Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. <i>European Heart Journal</i> , 2005, 26, 906-913.	2.2	150
309	PNMT Transgenic Mice Have an Aggressive Phenotype. <i>Hormone and Metabolic Research</i> , 2005, 37, 159-163.	1.5	16
310	Precisely Wrong? Urinary Fractionated Metanephrines and Peer-Based Laboratory Proficiency Testing. <i>Clinical Chemistry</i> , 2005, 51, 472-474.	3.2	23
311	Different expression of catecholamine transporters in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. <i>European Journal of Endocrinology</i> , 2005, 153, 551-563.	3.7	57
312	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2005, 12, 263-272.	3.1	47
313	Pheochromocytoma. <i>Lancet, The</i> , 2005, 366, 665-675.	13.7	1,462
314	Stress Dose of Hydrocortisone Is Not Beneficial in Patients with Classic Congenital Adrenal Hyperplasia Undergoing Short-Term, High-Intensity Exercise. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3679-3684.	3.6	64
315	Patients with Classic Congenital Adrenal Hyperplasia Have Decreased Epinephrine Reserve and Defective Glucose Elevation in Response to High-Intensity Exercise. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 591-597.	3.6	64
316	Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. <i>Endocrine-Related Cancer</i> , 2004, 11, 897-911.	3.1	184
317	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , 2004, 11, 423-436.	3.1	299
318	Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 1227-1232.	2.7	15
319	Diagnosis and Localization of Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 907-910.	2.7	40
320	Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. <i>Endocrine Reviews</i> , 2004, 25, 568-580.	20.1	145
321	Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism?. <i>Annals of the New York Academy of Sciences</i> , 2004, 1018, 224-230.	3.8	49
322	Pheochromocytoma: Diagnosis and management update. <i>Current Hypertension Reports</i> , 2004, 6, 477-484.	3.5	76
323	Inhibition of uptake-1 activity in the human heart in a hypernoradrenergic state. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, P54.	4.7	0
324	Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine. <i>Pharmacological Reviews</i> , 2004, 56, 331-349.	16.0	849

#	ARTICLE	IF	CITATIONS
325	Normetanephrine and Metanephrine. , 2004, , 387-390.		0
326	Pheochromocytoma as an endocrine emergency. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 121-128.	5.7	87
327	Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor. Endocrine Pathology, 2003, 14, 193-212.	9.0	61
328	Sources and Significance of Plasma Levels of Catechols and Their Metabolites in Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 305, 800-811.	2.5	355
329	Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2). FASEB Journal, 2003, 17, 1-13.	0.5	73
330	Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2656-2666.	3.6	447
331	Tyrosinase: a developmentally specific major determinant of peripheral dopamine. FASEB Journal, 2003, 17, 1248-1255.	0.5	81
332	Biochemical Diagnosis of Pheochromocytoma—Is it Time to Switch to Plasma-Free Metanephrines?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 550-552.	3.6	66
333	Principles of Catecholamine Biosynthesis, Metabolism and Release. , 2003, 31, 1-25.		29
334	Superiority of 6-[18F]-Fluorodopamine Positron Emission Tomography Versus [131I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4083-4087.	3.6	237
335	Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120.		12
336	Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106.		54
337	Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. Endocrine Practice, 2003, 9, 310-314.	2.1	25
338	Pheochromocytoma: Rediscovery as a Catecholamine-Metabolizing Tumor. Endocrine Pathology, 2003, 14, 193-212.	9.0	6
339	Adrenomedullary Function May Predict Phenotype and Genotype in Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3031-3037.	3.6	59
340	Children with Classic Congenital Adrenal Hyperplasia Have Elevated Serum Leptin Concentrations and Insulin Resistance: Potential Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2114-2120.	3.6	136
341	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1955-1960.	3.6	104
342	Pubertal and Gender-Related Changes in the Sympathoadrenal System in Healthy Children. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5038-5043.	3.6	76

#	ARTICLE	IF	CITATIONS
343	Cardiac Sympathetic Dysautonomia in Chronic Orthostatic Intolerance Syndromes. <i>Circulation</i> , 2002, 106, 2358-2365.	1.6	96
344	Biochemical Diagnosis of Pheochromocytoma. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1427-34.	7.4	994
345	Increased cardiac sympathetic drive in renovascular hypertension. <i>Journal of Hypertension</i> , 2002, 20, 1181-1187.	0.5	44
346	Diagnostic Localization of Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 170-176.	3.8	60
347	Simultaneous development of pheochromocytomas in prepubertal siblings with von Hippel-Lindau syndrome. <i>Journal of Pediatrics</i> , 2002, 140, 625-628.	1.8	3
348	Aldose reductase: An aldehyde scavenging enzyme in the intraneuronal metabolism of norepinephrine in human sympathetic ganglia. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2002, 96, 131-139.	2.8	17
349	Effects of Risperidone on the Peripheral Noradrenergic System in Patients with Schizophrenia A Comparison with Clozapine and Placebo. <i>Neuropsychopharmacology</i> , 2002, 27, 293-300.	5.4	24
350	Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. <i>Current Hypertension Reports</i> , 2002, 4, 250-255.	3.5	25
351	Catecholamine Phenotyping: Clues to the Diagnosis, Treatment, and Pathophysiology of Neurogenetic Disorders. <i>Journal of Neurochemistry</i> , 2002, 67, 1781-1790.	3.9	11
352	Chromaffin cell function and structure is impaired in corticotropin-releasing hormone receptor type 1-null mice. <i>Molecular Psychiatry</i> , 2002, 7, 967-974.	7.9	29
353	New Advances in the Biochemical Diagnosis of Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2002, 970, 29-40.	3.8	68
354	Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1955-1960.	3.6	28
355	Adrenomedullary Function May Predict Phenotype and Genotype in Classic 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3031-3037.	3.6	13
356	The Adrenal Medulla. , 2002, , 183-222.		1
357	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2001, 134, 315.	3.9	512
358	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2001, 2, 297-311.	5.7	156
359	The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, 91, 35-62.		292
360	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1999-2008.	3.6	262

#	ARTICLE	IF	CITATIONS
361	6-[¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. <i>Hypertension</i> , 2001, 38, 6-8.	2.7	215
362	Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. <i>Journal of the National Cancer Institute</i> , 2001, 93, 648-649.	6.3	83
363	The Importance of Adrenocortical Glucocorticoids for Adrenomedullary and Physiological Response to Stress: A Study in Isolated Glucocorticoid Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5920-5924.	3.6	69
364	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	3.6	51
365	Free or Total Metanephrines for Diagnosis of Pheochromocytoma: What Is the Difference?. <i>Clinical Chemistry</i> , 2001, 47, 988-989.	3.2	47
366	The Importance of Adrenocortical Glucocorticoids for Adrenomedullary and Physiological Response to Stress: A Study in Isolated Glucocorticoid Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5920-5924.	3.6	15
367	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	3.6	40
368	Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. , 2000, 60, 552-558.		82
369	Adrenergic and Noradrenergic Plasma Levels in Lesch-Nyhan Disease. <i>Neuropsychopharmacology</i> , 2000, 22, 320-326.	5.4	5
370	Effect of glipizide on dopamine synthesis, release and metabolism in PC12 cells. <i>European Journal of Pharmacology</i> , 2000, 388, 147-154.	3.5	12
371	3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. <i>Brain Research</i> , 2000, 868, 191-201.	2.2	99
372	Acidic dopamine metabolites are actively extruded from PC12 cells by a novel sulfonylurea-sensitive transporter. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2000, 361, 654-664.	3.0	17
373	Deletion of tyrosine hydroxylase gene reveals functional interdependence of adrenocortical and chromaffin cell system in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14742-14747.	7.1	50
374	Adrenomedullary Dysplasia and Hypofunction in Patients with Classic 21-Hydroxylase Deficiency. <i>New England Journal of Medicine</i> , 2000, 343, 1362-1368.	27.0	229
375	Haploinsufficiency of <i>steroidogenic factor-1</i> in mice disrupts adrenal development leading to an impaired stress response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14488-14493.	7.1	167
376	Differentiated Response of the Sympathetic Nervous System to Angiotensin-Converting Enzyme Inhibition in Hypertension. <i>Hypertension</i> , 2000, 36, 543-548.	2.7	31
377	Catecholamine Synthesis is Mediated by Tyrosinase in the Absence of Tyrosine Hydroxylase. <i>Journal of Neuroscience</i> , 1999, 19, 3519-3526.	3.6	119
378	Hyperleptinaemia does not correlate with plasma catecholamine levels in chronic heart failure. <i>European Heart Journal</i> , 1999, 20, 1051-1052.	2.2	12

#	ARTICLE	IF	CITATIONS
379	Increased Sympathetic Nerve Activity in Renovascular Hypertension. <i>Circulation</i> , 1999, 99, 2537-2542.	1.6	163
380	Plasma Normetanephrine and Metanephrine for Detecting Pheochromocytoma in von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. <i>New England Journal of Medicine</i> , 1999, 340, 1872-1879.	27.0	335
381	Splanchnic circulation and regional sympathetic outflow during peroperative PEEP ventilation in humans. <i>British Journal of Anaesthesia</i> , 1999, 82, 838-842.	3.4	29
382	Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. <i>Biomedical Applications</i> , 1999, 729, 347-353.	1.7	36
383	Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats. <i>Neurochemical Research</i> , 1999, 24, 25-32.	3.3	21
384	Aldose reductase, a key enzyme in the oxidative deamination of norepinephrine in rats. <i>Biochemical Pharmacology</i> , 1999, 58, 517-524.	4.4	22
385	Mechanism of Peripheral Noradrenergic Stimulation by Clozapine. <i>Neuropsychopharmacology</i> , 1999, 20, 29-34.	5.4	56
386	Lack of leptin suppression in response to hypersecretion of catecholamines in pheochromocytoma patients. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 543-545.	3.4	37
387	Sources and Physiological Significance of Plasma Dopamine Sulfate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2523-2531.	3.6	95
388	Aldo-Keto Reductases in Norepinephrine Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 1999, 463, 459-463.	1.6	2
389	Sources and Physiological Significance of Plasma Dopamine Sulfate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2523-2531.	3.6	20
390	Norepinephrine Spillover in Forearm and Subcutaneous Adipose Tissue before and after Eating. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2815-2819.	3.6	20
391	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2175-2185.	3.6	219
392	Dopamine Produced by the Stomach May Act as a Paracrine/ Autocrine Hormone in the Rat. <i>Neuroendocrinology</i> , 1998, 67, 336-348.	2.5	48
393	Determinants of cardiac tyrosine hydroxylase activity during exercise-induced sympathetic activation in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998, 274, R626-R634.	1.8	15
394	Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998, 275, R165-R173.	1.8	25
395	Plasma Metanephrines Are Markers of Pheochromocytoma Produced by Catechol-O-Methyltransferase Within Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2175-2185.	3.6	57
396	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. <i>Stress</i> , 1997, 2, 113-122.	1.8	15

#	ARTICLE	IF	CITATIONS
397	Substantial Production of Dopamine in the Human Gastrointestinal Tract. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3864-3871.	3.6	301
398	SYMPATHETIC AND RENIN-ANGIOTENSIN ACTIVATION DURING GRADED HYPOVOLEMIA IN PIGS. <i>Shock</i> , 1997, 8, 378-384.	2.1	41
399	Catecholamine Metabolism. <i>Advances in Pharmacology</i> , 1997, , 273-292.	2.0	12
400	Genetic Deficiencies of Monoamine Oxidase Enzymes: A Key to Understanding the Function of the Enzymes in Humans. <i>Advances in Pharmacology</i> , 1997, 42, 297-301.	2.0	10
401	Clues to the Diagnosis of Pheochromocytoma from the Differential Tissue Metabolism of Catecholamines. <i>Advances in Pharmacology</i> , 1997, 42, 374-377.	2.0	5
402	Sympathetic Carondioneuropathy in Dysautonomias. <i>Advances in Pharmacology</i> , 1997, 42, 615-619.	2.0	5
403	Sympathetic Cardioneuropathy in Dysautonomias. <i>New England Journal of Medicine</i> , 1997, 336, 696-702.	27.0	309
404	Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. <i>Journal of the Autonomic Nervous System</i> , 1997, 66, 145-148.	1.9	29
405	Cardiorenal epinephrine kinetics: evidence for neuronal release in the human heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1997, 273, H2178-H2185.	3.2	14
406	Hemodynamic, sympathetic and angiotensin II responses to PEEP ventilation before and during administration of isoflurane. <i>Acta Anaesthesiologica Scandinavica</i> , 1997, 41, 41-48.	1.6	27
407	Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites. <i>Neuropsychopharmacology</i> , 1997, 16, 276-284.	5.4	32
408	Tyrosine hydroxylase assay for detection of low levels of enzyme activity in peripheral tissues. <i>Biomedical Applications</i> , 1997, 694, 317-324.	1.7	15
409	Intracoronary blockade of angiotensinâ€converting enzyme in humans: Interaction with cardiac sympathetic neurotransmission?. <i>Acta Physiologica Scandinavica</i> , 1997, 161, 15-22.	2.2	8
410	Increased Cardiac Adrenergic Drive Precedes Generalized Sympathetic Activation in Human Heart Failure. <i>Circulation</i> , 1997, 95, 169-175.	1.6	255
411	Attenuated Cardiac Sympathetic Responsiveness During Dynamic Exercise in Patients With Heart Failure. <i>Circulation</i> , 1997, 95, 940-945.	1.6	33
412	Left Ventricular Norepinephrine and Epinephrine Kinetics at Birth in Lambs. <i>Circulation Research</i> , 1997, 81, 438-447.	4.5	7
413	A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 10377-10382.	7.1	112
414	Sympathetic discharge to mesenteric organs and the liver. Evidence for substantial mesenteric organ norepinephrine spillover.. <i>Journal of Clinical Investigation</i> , 1996, 97, 1640-1646.	8.2	70

#	ARTICLE	IF	CITATIONS
415	Plasma Metanephrines in the Diagnosis of Pheochromocytoma. <i>Annals of Internal Medicine</i> , 1996, 124, 695.	3.9	2
416	Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase. <i>Neuropsychopharmacology</i> , 1996, 15, 296-301.	5.4	9
417	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1996, 354, 287-94.	3.0	34
418	Mesenteric Organ Production, Hepatic Metabolism, and Renal Elimination of Norepinephrine and Its Metabolites in Humans. <i>Journal of Neurochemistry</i> , 1996, 66, 1565-1573.	3.9	96
419	Cardiac Sympathetic Nerve Function in Congestive Heart Failure. <i>Circulation</i> , 1996, 93, 1667-1676.	1.6	376
420	Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes.. <i>Journal of Clinical Investigation</i> , 1996, 97, 1010-1019.	8.2	139
421	Plasma Metanephrines in the Diagnosis of Pheochromocytoma. <i>Annals of Internal Medicine</i> , 1995, 123, 101.	3.9	222
422	Splanchnic and Renal Sympathetic Activity in Relation to Hemodynamics During Isoflurane Administration in Pigs. <i>Anesthesia and Analgesia</i> , 1995, 80, 135-142.	2.2	8
423	Splanchnic and Renal Sympathetic Activity in Relation to Hemodynamics During Isoflurane Administration in Pigs. <i>Anesthesia and Analgesia</i> , 1995, 80, 135-142.	2.2	12
424	Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. <i>Clinical Science</i> , 1995, 88, 533-542.	4.3	105
425	Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. <i>American Journal of Cardiology</i> , 1995, 76, 125-130.	1.6	131
426	Is There a Third Peripheral Catecholaminergic System? Endogenous Dopamine as an Autocrine/ Paracrine Substance Derived from Plasma DOPA and Inactivated by Conjugation. <i>Hypertension Research</i> , 1995, 18, S93-S99.	2.7	69
427	Differential actions of desipramine on sympathoadrenal release of noradrenaline and adrenaline.. <i>British Journal of Clinical Pharmacology</i> , 1995, 40, 263-265.	2.4	14
428	Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 3009-3017.	3.6	115
429	Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1994, 653, 131-138.	1.7	213
430	Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1994, 349, 259-69.	3.0	27
431	The influence of aging on the plasma concentration and renal clearance of homovanillic acid. <i>Psychoneuroendocrinology</i> , 1994, 19, 33-41.	2.7	7
432	In vivo kinetics of catecholamines. <i>Autonomic and Autacoid Pharmacology</i> , 1994, 14, 7-8.	0.6	5

#	ARTICLE	IF	CITATIONS
433	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. <i>Journal of the Autonomic Nervous System</i> , 1994, 50, 93-107.	1.9	39
434	Regional homovanillic acid production in humans. <i>Life Sciences</i> , 1993, 53, 63-75.	4.3	49
435	Concentrations of noradrenaline at neuronal uptakes sites during sympathetic nervous inhibition and activation in rabbits. <i>Neurochemistry International</i> , 1993, 22, 493-499.	3.8	5
436	Positron emission tomographic imaging of cardiac sympathetic Innervation using 6-[18 F]Fluorodopamine: Initial findings in humans. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1961-1971.	2.8	106
437	Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake.. <i>Circulation</i> , 1993, 88, 136-145.	1.6	197
438	Cardiac Noradrenergic Function One Year Following Cardiac Transplantation. <i>Blood Pressure</i> , 1993, 2, 252-261.	1.5	12
439	Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine.. <i>Circulation</i> , 1992, 85, 1775-1785.	1.6	114
440	Increased norepinephrine spillover into the jugular veins in essential hypertension.. <i>Hypertension</i> , 1992, 19, 62-69.	2.7	101
441	Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans.. <i>Journal of Physiology</i> , 1992, 453, 45-58.	2.9	265
442	Increased cardiac production of dihydroxyphenylalanine (DOPA) during sympathetic stimulation in anaesthetized dogs. <i>Neurochemistry International</i> , 1992, 21, 37-44.	3.8	19
443	Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1992, 345, 160-171.	3.0	42
444	Direct determination of homovanillic acid release from the human brain, and indicator of central dopaminergic activity. <i>Life Sciences</i> , 1991, 49, 1061-1072.	4.3	93
445	Regional extraction of circulating norepinephrine, DOPA, and dihydroxyphenylglycol in humans. <i>Journal of the Autonomic Nervous System</i> , 1991, 34, 17-35.	1.9	46
446	Noradrenaline reuptake and plasma dihydroxyphenylglycol during sustained changes in sympathetic activity in rabbits. <i>Journal of the Autonomic Nervous System</i> , 1991, 32, 217-231.	1.9	15
447	Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. <i>Journal of Hypertension</i> , 1991, 9, 417-423.	0.5	37
448	Differential Effects of Central and Peripheral Desipramine on Sympathoadrenal Function and Heart Rate in Conscious Rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 17, 519-531.	1.9	10
449	Neuronal Re-Uptake of Noradrenaline by Sympathetic Nerves in Humans. <i>Clinical Science</i> , 1991, 80, 257-263.	4.3	28
450	Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. <i>Clinical Autonomic Research</i> , 1991, 1, 187-194.	2.5	61

#	ARTICLE	IF	CITATIONS
451	Is adrenaline released by sympathetic nerves in man?. <i>Clinical Autonomic Research</i> , 1991, 1, 103-108.	2.5	29
452	ADRENALINE RELEASE BY THE HUMAN HEART. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1991, 18, 67-70.	1.9	9
453	Neuronal reuptake of norepinephrine and production of dihydroxyphenylglycol by cardiac sympathetic nerves in the anesthetized dog.. <i>Circulation</i> , 1991, 84, 1354-1363.	1.6	54
454	Positron emission tomographic imaging of cardiac sympathetic innervation and function.. <i>Circulation</i> , 1990, 81, 1606-1621.	1.6	114
455	Parallel increases in noradrenaline reuptake and release into plasma during activation of the sympathetic nervous system in rabbits. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1990, 342, 328-35.	3.0	23
456	Simultaneous determination of plasma noradrenaline and adrenaline kinetics. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1990, 341, 192-9.	3.0	118
457	Differences in the Neuronal Removal of Circulating Epinephrine and Norepinephrine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 1710-1720.	3.6	43
458	Opposite changes in turnover of noradrenaline and dopamine in the CNS of ethanol-dependent mice. <i>Neuropharmacology</i> , 1990, 29, 37-45.	4.1	27
459	Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy.. <i>Circulation</i> , 1989, 79, 836-844.	1.6	88
460	Plasma Dihydroxyphenylalanine and Total Body and Regional Noradrenergic Activity in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 68, 247-255.	3.6	45
461	Plasma levels of catechols during reflexive changes in sympathetic nerve activity. <i>Neurochemical Research</i> , 1989, 14, 523-531.	3.3	16
462	Pharmacologic and Tracer Methods to Study Sympathetic Function in Primary Hypertension. <i>Clinical and Experimental Hypertension</i> , 1989, 11, 173-189.	0.3	9
463	Implications of Plasma Levels of Catechols in the Evaluation of Sympathoadrenomedullary Function. <i>American Journal of Hypertension</i> , 1989, 2, 133S-139S.	2.0	10
464	Plasma dihydroxyphenylglycol for estimation of noradrenaline neuronal re-uptake in the sympathetic nervous system in vivo. <i>Clinical Science</i> , 1989, 76, 171-182.	4.3	63
465	Urinary excretion of dihydroxyphenylalanine and dopamine during alterations of dietary salt intake in humans. <i>Clinical Science</i> , 1989, 76, 517-522.	4.3	64
466	Simultaneous determination of endogenous catechols and exogenous 2- and 6-fluorinated catechols in tissue and plasma using liquid chromatography with electrochemical detection. <i>Biomedical Applications</i> , 1988, 431, 156-162.	1.7	9
467	Source and Physiological Significance of Plasma 3,4-Dihydroxyphenylalanine in the Rat. <i>Journal of Neurochemistry</i> , 1988, 51, 1204-1213.	3.9	42
468	Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. <i>Journal of the Autonomic Nervous System</i> , 1988, 24, 1-14.	1.9	96

#	ARTICLE	IF	CITATIONS
469	In vivo measurement of neuronal uptake of norepinephrine in the human heart.. Circulation, 1988, 78, 41-48.	1.6	157
470	Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans.. Journal of Clinical Investigation, 1988, 81, 213-220.	8.2	229
471	Neuronal Source of Plasma Dihydroxyphenylalanine. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 856-861.	3.6	88
472	Plasma norepinephrine pharmacokinetics during mental challenge.. Psychosomatic Medicine, 1987, 49, 591-605.	2.0	80
473	DISSOCIATION BETWEEN CORTICOTROPHIN AND CATECHOLAMINE RESPONSES TO ISOPRENALINE IN HUMANS. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 337-341.	1.9	9
474	Effects of ethanol on cardiovascular and catecholamine responses to mental stress. Journal of Psychosomatic Research, 1986, 30, 93-102.	2.6	23
475	The effects of acute and chronic ingestion of ethanol on the autonomic nervous system. Drug and Alcohol Dependence, 1986, 18, 319-328.	3.2	76
476	Plasma 3, 4-Dihydroxyphenylalanine (Dopa) and Catecholamines in Neuroblastoma or Pheochromocytoma. Annals of Internal Medicine, 1986, 105, 887.	3.9	49
477	Analytical differences between the determination of plasma catecholamines by liquid chromatography with electrochemical detection and by radioenzymatic assay. Biomedical Applications, 1986, 377, 328-333.	1.7	24
478	COMPARISON OF NORADRENALINE AND ISOPRENALINE REMOVAL IN THE CANINE HINDLIMB AND KIDNEY. Clinical and Experimental Pharmacology and Physiology, 1986, 13, 777-781.	1.9	7
479	Increased voluntary ethanol intake after dietary salt-loading in rats. Pharmacology Biochemistry and Behavior, 1986, 24, 1825-1827.	2.9	0
480	Vasopressin Concentrations during Alcohol Withdrawal. Addiction, 1985, 80, 195-199.	3.3	38
481	Ethanol-induced inhibition of the drinking response to hypertonic saline in the rat. Pharmacology Biochemistry and Behavior, 1985, 22, 493-496.	2.9	2
482	No effect of ethanol ingestion on beta-adrenoceptor-mediated circulatory responses to isoprenaline in man.. British Journal of Clinical Pharmacology, 1985, 20, 684-687.	2.4	7
483	No improvement in ethanol-induced memory deficits after administration of a vasopressin analog. Life Sciences, 1985, 37, 2499-2505.	4.3	6
484	Effects of ethanol ingestion on alpha-adrenoceptor-mediated circulatory responses in man.. British Journal of Clinical Pharmacology, 1984, 18, 581-586.	2.4	21
485	Growth Hormone, Vasopressin, Cortisol, and Catecholamine Responses to Insulin Hypoglycemia in Alcoholics. Alcoholism: Clinical and Experimental Research, 1984, 8, 33-36.	2.4	18
486	Effects of ethanol on plasma catecholamines and norepinephrine clearance. Clinical Pharmacology and Therapeutics, 1983, 34, 143-147.	4.7	57

#	ARTICLE	IF	CITATIONS
487	BRAIN WATER DURING ALCOHOL WITHDRAWAL. <i>Lancet, The</i> , 1982, 319, 50.	13.7	14
488	Treatment of Pheochromocytoma. , 0, , 109-113.		0
489	Current Trends in Genetics of Pheochromocytoma. , 0, , 30-40.		2
490	Catecholamines and Adrenergic Receptors. , 0, , 41-71.		2
491	Current Trends in Biochemical Diagnosis of Pheochromocytoma. , 0, , 72-92.		2
492	Current Trends in Localization of Pheochromocytoma. , 0, , 93-108.		1
493	Future Trends and Perspectives. , 0, , 114-119.		0
494	Clinical Presentation of Pheochromocytoma. , 0, , 8-29.		1